Videos

“For most men, we can identify the specific site or sites of recurrence, and thereby use a more directed therapy that specifically targets the abnormal sites,” says Gerald L. Andriole, MD.

“The good news for patients is that the survival and radiographic progression-free survival [were] substantially improved in all subsets,” says Andrew J. Armstrong, MD, MSc.

"It’s an important topic to debate,” says Scott E. Eggener, MD.

“There are so many advances in prostate cancer, many of which are actually targeted,” says Alicia K. Morgans, MD, MPH.

“[I focused on] why this such an important topic and how we might better counsel our patients,” says Kristen Scarpato, MD, MPH.

“One of the hardest things and one of the most important things is to figure out what part of urology excites you the most and look for those opportunities,” says Eila C. Skinner, MD.

"I think for the right patient, Cysview technology has a big deliverable,” says Alexander Kutikov, MD, FACS.

“My talk [highlights] unmet research needs that need to be addressed to further improve the adjuvant treatment landscape for our patients,” said Pavlos Msaouel, MD, PhD.

“Overall, my take is that even with an intense PSMA-targeted radionuclide regimen, I think the chance of a response… at least by PSA, is higher with stronger baseline PSMA imaging,” says Scott T. Tagawa, MD, MS, FACP.

“No question, we see that there’s a lot of heterogeneity in how penile cancer is managed across the United States,” says Philippe E. Spiess, MD, MS, FACS.

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

"Some of the discussion going on right now is how to improve the morbidity of bladder cancer treatment by pursuing such things…as bladder sparing approaches when feasible…and so, I think that’s very exciting,” says Mohummad M. Siddiqui, MD.

“The idea was really to bring together a multidisciplinary group of experts and to discuss…highly relevant, translational research that’s going on, and to…address some of the really critical clinical questions as well,” says Seth P. Lerner, MD, FACS.

“We are having a wealth of new medications that are helping our patients. Primarily with advanced disease, but…maybe there are going to be some applications to move that earlier and earlier in the in the disease process,” says Christopher B. Anderson, MD, MPH.

Kyle Wood, MD, reviews data and clinical implications for the use of reloxaliase in enteric hyperoxaluria as seen in the phase 3 URIROX-1 trial and shares insight on additional ongoing trials.

Ashley E. Ross, MD, PhD, leads the discussion on risk stratification in advanced prostate cancer and approaching prostate cancer screening.

Bobby Liaw, MD; Neal Shore, MD, FACS; and Vivek K. Narayan, MD, MS, discuss the incidence and prevalence of advanced prostate cancer, including mCSPC and nmCRPC.

“While this study does offer a lot of promise for the treatment options that we can offer to these patients, it does also highlight the need for further prospective trials to evaluate the efficacy of this treatment, as well as the treatments of all the different surgical options available to patients who are suffering from BPH,” says Evan Garden.

“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.

“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.

“I would say what RTOG-0815 has provided is data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.

“I think the key elements are that you should know about Aquablation if you are treating BPH in consideration for your patients and care, especially those who are looking for a more durable response and to maintain their ejaculation,” says Kevin Zorn, MD, FRCSC, FACS.

“New things are being developed and, I believe, at the moment showing great initiative and resolve,” says Justin Chee, MD.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.

Welcome to another installment of Uranimals, our video series featuring urologists and their pets. From a dog duo to a group of animals living mountainside, check out our latest guests!

“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.

“Fortunately, since things have…eased up with the pandemic, I would say probably in the last 6 months I've noticed that the BCG availability has improved,” says Chad R. Ritch, MD, MBA, FACS.